

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CLARITY MEDICAL GROUP HOLDING LIMITED

### 清晰醫療集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

### PROFIT WARNING

This announcement is made by Clarity Medical Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of the Company hereby informs the shareholders of the Company and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2023 and other information currently available to the Company, the Company is expected to record a net loss of not more than HK\$24.0 million for the six months ended 30 September 2023 (the “**Interim Period**”) as compared to a net profit of approximately HK\$7.9 million recorded for the six months ended 30 September 2022.

The expected turnaround is primarily attributable to the expected decrease in revenue and increase in operating expenses. Due to the economic downturn and increased competition from other industry players, the Group adopted a more competitive pricing strategy during the Interim Period which had affected the Group’s revenue.

On the other hand, the increase in operating expenses was primarily due to the increase in staff costs, lease expenses, depreciation expenses and business development expenses to support the Group’s business expansion, particularly the establishment of a new medical centre in Tsim Sha Tsui, and to maintain the Group’s competitiveness.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 September 2023. The information contained in this announcement is only a preliminary assessment based on the unaudited consolidated management accounts of the Group for the six months ended 30 September 2023 and the information currently available for the time being, which have not been audited nor reviewed by the Company's auditors and have not been confirmed by the audit committee of the Company and is subject to adjustments. The financial results of the Group for the six months ended 30 September 2023 will be set out in the interim results announcement of the Company which is expected to be published by the end of November 2023.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CLARITY MEDICAL GROUP HOLDING LIMITED**  
**WU Ting Yuk Anthony**  
*Non-Executive Director and Chairman*

Hong Kong, 20 October 2023

*As at the date of this announcement, the Board comprises Mr. HUI Yung Chris, Dr. TSE Wai Ip and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. NG Roy and Ms. ZHAO Wei as non-executive Directors and Mr. LI Michael Hankin, Mr. MA Wai Hung Vincent and Professor LAU Wan Yee Joseph as independent non-executive Directors.*